Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-11-14 |
2024-09 |
-0.11 |
N/A |
N/A |
N/A |
2024-08-07 |
2024-06 |
-0.08 |
-0.04 |
0.04 |
50.00% |
2024-05-08 |
2024-03 |
-0.38 |
-0.23 |
0.15 |
39.47% |
2024-05-08 |
2024-03 |
-0.38 |
N/A |
N/A |
N/A |
2024-03-21 |
2023-12 |
-0.35 |
-0.42 |
-0.07 |
-20.00% |
2024-03-21 |
2023-12 |
-0.35 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-09-10 |
Maxim Group |
Upgrade |
|
Buy |
2023-06-05 |
HC Wainwright & Co. |
Upgrade |
|
Neutral |
2023-03-22 |
HC Wainwright & Co. |
Downgrade |
Buy |
Neutral |
2023-02-06 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2022-02-01 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2022-01-23 |
ThinkEquity |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2021-10-21 |
DICK EVAN G PH.D. |
Officer |
87.14K |
Conversion of Exercise of derivative security |
2023-02-20 |
LEHR MARTIN A |
Chief Executive Officer |
979.89K |
Purchase |
2022-12-08 |
LEVIT ALEX C. |
Officer |
61.98K |
Purchase |
2022-12-15 |
MINAI-AZARY JENNIFER LYNN |
Chief Financial Officer |
40.00K |
Purchase |
2022-08-15 |
SAHMOUD TAREK M.D., PH.D. |
Officer |
10.00K |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Ally Bridge Group (NY) LLC |
653.40K |
1.05M |
4.09% |
2023-06-29 |
Vanguard Group Inc |
574.70K |
919.52K |
3.60% |
2023-06-29 |
Affinity Asset Advisors, Llc |
267.57K |
428.12K |
1.68% |
2023-06-29 |
HighTower Advisors, LLC |
125.85K |
201.36K |
0.79% |
2023-06-29 |
Geode Capital Management, LLC |
107.23K |
171.57K |
0.67% |
2023-06-29 |
Bridgeway Capital Management, Inc. |
105.81K |
169.29K |
0.66% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
573.40K |
917.44K |
3.59% |
2023-06-29 |
Bridgeway Funds Inc-Ultra Small Company Fund |
105.81K |
169.29K |
0.66% |
2023-05-30 |
Fidelity Extended Market Index Fund |
38.94K |
33.87K |
0.24% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
13.62K |
11.85K |
0.09% |
2023-05-30 |
Fidelity NASDAQ Composite Index Fund |
2.23K |
1.94K |
0.01% |
2023-06-29 |
Vanguard Extended Market Index Fund |
1.30K |
2.08K |
0.01% |